MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent
MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDA’s Approval of a Telomerase Inhibitor Agent Therapy
MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent
MAIA Biotechnology Reveals New Clinical Data Showing THIO’s Strong Efficacy in Non-Small Cell Lung Cancer
MAIA Biotechnology to Present at the BIO International Convention 2024
MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement
MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement
MAIA Biotechnology Announces $1.00 Million Private Placement
MAIA Biotechnology to Present at Two Investor Conferences in April 2024